A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization

Cells Tissues Organs

Volumn 177, Issue 3, 2004, Pages 124-131

  Panelli, Monica C ^a   Martin, Brian ^b   Nagorsen, Dirk ^a   Wang, Ena ^a   Smith, Kina ^a   Monsurro, Vladia ^a   Marincola, Francesco M ^a  

^a CLINICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Chemokines; Cytokines; Immunization; Interleukin 2; Melanoma

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 2;

ACTIVE IMMUNIZATION; CIRCULATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RESPONSE; EX VIVO STUDY; GENETIC TRANSCRIPTION; GENOMICS; HUMAN; HYPOTHESIS; MELANOMA; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEOMICS; RNA TRANSLATION; T LYMPHOCYTE; TUMOR CELL; TUMOR REGRESSION;

CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYTOKINES; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-2; MELANOMA; MODELS, BIOLOGICAL; PROTEOMICS; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION, GENETIC;

EID: 4644357717     PISSN: 14226405     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079986     Document Type: Conference Paper

References (23)

1. Boccoli, G., R. Masciulli, E.M. Ruggeri, P. Carlini, G. Gianella, E. Montesoro, G. Mastroberardino, G. Isacchi, U. Testa, F. Calabresi, et al. (1990) Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res 50: 5795-5800.
2. Boon, T., P.G. Coulie, B. Van den Eynde (1997) Tumor antigens recognized by T cells. Immunol Today 18: 267-268.
3. Cormier, J.N., M.L. Salgaller, T. Prevette, K.C. Barracchini, L. Rivoltini, N.P. Restifo, S.A. Rosenberg, F.M. Marincola (1997) Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 3: 37-44.
4. Deehan, D.J., S.D. Heys, W. Simpson, R. Herriot, J. Broom, O. Eremin (1994) Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2. Clin Exp Immunol 95: 366-372.
5. Eisen, M.B., P.T. Spellman, P.O. Brown, D. Botstein (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868.
6. Gordon, S. (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
7. Keen, L.J. (2002a) The extent and analysis of cytokine and cytokine receptor gene polymorphism. Transpl Immunol 10: 143-146.
8. Keen, L.J. (2002b) The study of polymorphism in cytokine and cytokine receptor genes. ASHI Q 26: 148-153.
9. Khani-Hanjani, A., D. Hoar, D. Horsman, D. Lacaille, A. Chalmers, P. Keown (2001) Identification of four novel dinucleotide repeat polymorphisms in the IL-2 and IL-2beta receptor genes. Hum Immunol 62: 368-370.
10. List, J., R.P. Moser, M. Steuer, W.G. Loudon, J.B. Blacklock, E.A. Grimm (1992) Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin-1 beta, interleukin-6, gamma-interferon and soluble interleukin-2 receptor (M r 55,000 protein). Cancer Res 52: 1123-1128.
11. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, A. Sica (2002) Macrophage polarization: tumor-associated macrophage as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
12. Marincola, F.M. (1994) Interleukin-2. Biol Ther Cancer Updates 4: 1-16.
13. Marincola, F.M., E. Wang, M. Herlyn, B. Seliger, S. Ferrone (2003) Tumors as elusive targets of T cell-directed immunotherapy. Trends Immunol 24: 335-342.
14. Masztalerz, A., N. Van Rooijen, W. Den Otter, L.A. Everse (2003) Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression. Cancer Immunol Immunother 52: 235-242.
15. Monsurro, V., D. Nagorsen, E. Wang, M. Provenzano, M.E. Dudley, S.A. Rosenberg, F.M. Marincola (2002) Functional heterogeneity of vaccine-induced CD8+ T cells. J Immunol 168: 5933-5942.
16. Panelli, M.C., E. Wang, G. Phan, M. Puhlman, L. Miller, G.A. Ohnmacht, H. Klein, F.M. Marincola (2002) Genetic-expression pro. ling of the response of peripheral mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 3: RESEARCH0035.
17. Rosenberg, S.A. (1997) Cancer vaccines based on the identi. cation of genes encoding cancer regression antigens. Immunol Today 18: 175-182.
18. Rosenberg, S.A., M.T. Lotze, J.C. Yang, P.M. Aebersold, W.M. Linehan, C.A. Seipp, D.E. White (1989) Experience with the use of highdose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474-484.
19. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, J.R. Wunderlich, M.R. Parkhurst, Y. Kawakami, C.A. Seipp, J.H. Einhorn, D.E. White (1998) Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327.
20. Turner, D., F. Choudhury, M. Reynard, D. Railton, C. Navarrete (2002) Typing of multiple single nucleotide polymorphisms in cytokine and receptor genes using SNaPshot. Hum Immunol 63: 508-513.
21. Wang, E., L. Miller, G.A. Ohnmacht, E. Liu, F.M. Marincola (2000) High fidelity mRNA amplification for gene profiling. Nature Biotechnol 18: 457-459.
22. Whittington, R., D. Faulds (1993) Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46: 446-514.
23. Yang, J.C., S.A. Rosenberg (1997) An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 3: S79-S84.